CLINICAL TRIALS PROFILE FOR DYMISTA
✉ Email this page to a colleague
All Clinical Trials for Dymista
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01794741 ↗ | 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis | Completed | Meda Pharmaceuticals | Phase 3 | 2013-02-01 | This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis |
| NCT01915823 ↗ | Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR) | Completed | Meda Pharmaceuticals | Phase 3 | 2013-07-01 | The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis. |
| NCT02238353 ↗ | AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) | Unknown status | Universitaire Ziekenhuizen Leuven | Phase 4 | 2014-10-01 | Comparative analysis of the efficacy of intranasal MP29-02 (a novel formulation of azelastine and FP) has already been conducted in patients with moderate-to-severe seasonal AR. The combination formulation appeared to be superior in these patients with better symptomatic relief. However, objective analysis of the effect of this treatment on nasal mediators and/or nasal hyperreactivity has not yet been performed and would help in understanding the additional benefit of the combination treatment over monotherapy with nasal corticosteroids. |
| NCT02249663 ↗ | Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™ | Unknown status | Teva Pharmaceuticals USA | Phase 3 | 2014-08-01 | To evaluate the therapeutic equivalence of a test formulation of Azelastine hydrochloride and Fluticasone propionate Nasal Spray to the reference listed drug, Dymista™ Nasal Spray in the relief of the signs and symptoms of Seasonal Allergic Rhinitis. |
| NCT02279563 ↗ | A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis | Unknown status | Apotex Inc. | Phase 2 | 2013-12-01 | This study is to evaluate the equivalence of generic Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray with that of the marketed drug, Dymista™ Nasal Spray, in the treatment of seasonal allergic rhinitis, and to evaluate the safety and tolerability of generic Azelastine Hydrochloride and Fluticasone Propionate nasal spray compared with Dymista™ nasal spray. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dymista
Condition Name
Clinical Trial Locations for Dymista
Trials by Country
Clinical Trial Progress for Dymista
Clinical Trial Phase
Clinical Trial Sponsors for Dymista
Sponsor Name
